Cellectis SA (CLLS) Earnings Date & Reports

Cellectis SA is a clinical stage biotechnological company, employing the core proprietary technologies to develop products based on gene-editing, with a portfolio of allogeneic Chimeric Antigen Receptor T-cells, or UCART, product candidates in the field of immuno-oncology and gene-edited hematopoietic stem and progenitor cells, or HSPC product candidates in other therapeutic indications... Show more

Industry: #Biotechnology

Get AI intraday signals

A.I. Advisor

published Earnings

CLLS is expected to report earnings to fall 6.14% to -20 cents per share on November 09

Cellectis SA CLLS Stock Earnings Reports

Q3'26

Est.

$-0.21

Q2'26

Beat

by $0.04

Q1'26

Beat

by $0.08

Q4'25

Beat

by $0.03

Q3'25

Beat

by $0.24

The last earnings report on August 06 showed earnings per share of -21 cents, beating the estimate of -25 cents. With 1.98K shares outstanding, the current market capitalization sits at 328.33M.

View a ticker or compare two or three

CLLS

Daily Signal:

Gain/Loss:

Interact to see
Advertisement

A.I.Advisor

published price charts

Last 5 trading days